Exhibit 99.1

FOR IMMEDIATE RELEASE

BioScrip reports FOURTH QUARTER 2012 financial results

Elmsford, NY – March 11, 2013 – BioScrip, Inc. (NASDAQ: BIOS) today announced 2012 fourth quarter financial results. Fourth quarter revenue from continuing operations was $180.7 million and the net loss from continuing operations was $1.4 million, or $0.03 per diluted share. Consolidated Adjusted EBITDA for the fourth quarter was $12.1 million, and consolidated adjusted earnings per diluted share for the fourth quarter was $0.04 per diluted share.

This quarter, the Company will also begin reporting adjusted earnings per diluted share (“Adjusted EPS”), which excludes the same elements in calculating Adjusted EBITDA (restructuring and other expenses, acquisition and integration expenses, stock-based compensation expense) as well as the impact of acquisition-related intangible amortization. Management believes that this non-GAAP financial measure provides useful supplemental information regarding the performance of our business operations and facilitates comparisons to our historical operating results.

As a result of the sale of the Company’s traditional and specialty pharmacy mail operations and community retail pharmacy stores on May 4, 2012 (the “Pharmacy Services Asset Sale”), the Company’s financial statements reflect the discontinued operations’ results for the three months ended December 31, 2012 and 2011, and assets transferred in the transaction as of December 31, 2012 and 2011, separate from the continuing operations of the business. The remaining assets and liabilities of the divested business that were not transferred as a part of the Pharmacy Services Asset Sale are included in continuing operations.

Fourth Quarter Highlights

· Revenue from continuing operations increased by $22.5 million, or 14.2%, as compared to the prior year;

· Gross profit from continuing operations was $60.4 million, or 33.4% of revenue, as compared to $58.6 million, or 37.0% of revenue, in the prior year period;

· Adjusted EBITDA from continuing operations was $12.1 million, compared to $11.6 million in the third quarter, a 4.3% sequential quarter improvement, despite the impact of Hurricane Sandy on the Northeast market; and,

· Entered into a definitive agreement to acquire HomeChoice Partners, Inc. (“HomeChoice”), a majority-owned subsidiary of DaVita HealthCare Partners Inc. (NYSE: DVA).

1

“We are pleased to report solid fourth quarter performance. Our consolidated results reflect continued progress in the execution of our strategic goals and growth in our infusion business,” said Rick Smith, President and Chief Executive Officer of BioScrip.

“Overall, 2012 was a year of positive progress and momentum for BioScrip. We accomplished a number of our key objectives towards repositioning the Company to focus on our infusion and home health businesses. In 2013, we will continue to build on our organic growth initiatives, which will be augmented with targeted acquisitions. The core drivers of organic growth will be delivering on our strong clinical programs, flexible go-to-market approach, and high-touch customer service model,” concluded Smith.

Results of Operations

Fourth Quarter 2012 versus Fourth Quarter 2011

Revenue from continuing operations for the fourth quarter of 2012 totaled $180.7 million, compared to $158.3 million for the same period a year ago, an increase of $22.5 million or 14.2%. Infusion Services segment revenue was $135.6 million in the fourth quarter, as compared to $102.5 million for the same period in 2011. The 32.4% increase was driven primarily by overall volume growth as well as the addition of the InfuScience acquisition. Home Health Services segment revenue was $18.3 million for the fourth quarter of 2012, as compared to $17.2 million in the prior year quarter. The 6.5% increase was primarily the result of volume growth offset by the previously announced reimbursement reductions from Medicare and the state of Tennessee TennCare program. PBM Services segment revenue was $26.8 million for the fourth quarter of 2012, compared to $38.6 million for the prior year period. The decrease was due primarily to a decline in the funded PBM business and a reduction in discount card revenues.

Consolidated gross profit for the fourth quarter of 2012 was $60.4 million, or 33.4% of revenue, compared to $58.6 million, or 37.0% of revenue, for the fourth quarter of 2011. The increase in gross profit was the result of growth in the volume of Infusion Services segment revenues and growth in the Home Health Services business. The decline in gross profit margin percentage resulted primarily from a shift in the therapy mix in the Infusion Services segment, as well as a decrease in home health reimbursement rates from certain government payors.

During the fourth quarter of 2012, Infusion Services Segment Adjusted EBITDA was $11.0 million, or 8.1% of segment revenue, compared to $9.9 million, or 9.7% of segment revenue in the prior year quarter, and $9.9 million, or 7.9% of segment revenue in the third quarter of 2012.

The Home Health Services Segment Adjusted EBITDA in the fourth quarter of 2012 was $1.8 million, or 10.1% of segment revenue. This compares to Segment Adjusted EBITDA of $1.5 million, or 8.7% of segment revenue, in the comparable prior year period, and $1.4 million, or 8.1% of segment revenue in the third quarter of 2012. The PBM Services Segment Adjusted EBITDA was $6.3 million, or 23.5% of segment

2

revenue, for the fourth quarter of 2012 compared to $9.3 million, or 24.0% of segment revenue, in the prior year quarter.

On a consolidated basis, BioScrip reported $12.1 million of Adjusted EBITDA during the fourth quarter of 2012, or 6.7% of total revenue, compared to $14.9 million, or 9.4% of total revenue, in the same period last year.

Interest expense in the fourth quarter of 2012 was $6.4 million compared to $6.2 million in the prior year period.

Income tax benefit for continuing operations in the fourth quarter was $1.8 million compared to an income tax expense of $2.8 million in the fourth quarter of 2011.

Net loss from continuing operations for the fourth quarter of 2012 was $1.4 million, or a loss of $0.03 per diluted share, compared to a net income of $2.6 million, or $0.05 per diluted share, for the fourth quarter of 2011.

Twelve Months Ended 2012 versus Twelve Months Ended 2011

Revenue from continuing operations for the twelve months ended December 31, 2012 totaled $662.6 million, compared to $554.5 million for the same period a year ago, a 19.5% increase. Infusion Services segment revenue was $481.6 million for the twelve months ended December 31, 2012, compared to $374.3 million for the same period in 2011. The 28.7% increase was driven primarily by an increase in volume growth and the InfuScience acquisition. Home Health Services segment revenue for the twelve months ended December 31, 2012 was $69.2 million, compared to $69.6 million in the prior year. The 0.6% decrease was primarily the result of reimbursement reductions as previously discussed. PBM Services segment revenue for the twelve months ended December 31, 2012 was $111.9 million, compared to $110.6 million for the prior year period. The 1.2% increase is primarily due to an increase in discount card program sales.

Consolidated gross profit for the twelve months ended December 31, 2012 was $225.0 million, or 33.9% of revenue, compared to $215.4 million, or 38.8% of revenue, in the comparable prior year period. The net increase in gross profit was due primarily to organic growth and the contribution from InfuScience. As previously disclosed, in connection with the Pharmacy Services Asset Sale, the Company provided certain lower margin services on behalf of key customers after the sale. Additionally, there was a substantial decrease in cross referrals of certain therapies from the specialty sales personnel affiliated with the divested business.

During the twelve months ended December 31, 2012, Infusion Services Segment Adjusted EBITDA was $36.8 million, or 7.6% of segment revenue, compared to $35.1 million, or 9.4% of segment revenue, in the prior year.

The Home Health Services Segment Adjusted EBITDA for the twelve months ended December 31, 2012 was $5.4 million, or 7.8% of segment revenue. This compares to Segment Adjusted EBITDA of $6.0 million, or 8.6% of segment revenue, in the prior

3

year. The PBM Services Segment Adjusted EBITDA was $25.7 million, or 22.9% of segment revenue, for the twelve months ended December 31, 2012 compared to $30.1 million, or 27.2% of segment revenue, in the prior year.

On a consolidated basis, BioScrip reported $41.1 million of Adjusted EBITDA for the twelve months ended December 31, 2012, or 6.2% of total revenue, compared to $47.9 million, or 8.6% of total revenue, in the same period last year.

Interest expense for the twelve months ended December 31, 2012 was $26.1 million compared to $25.5 million in the prior year.

Income tax benefit for continuing operations for the twelve months ended December 31, 2012 was $4.4 million, compared to an income tax expense of $0.4 million in 2011.

Net loss from continuing operations for the twelve months ended December 31, 2012 was $8.3 million, or $0.15 per diluted share, compared to a net loss of $0.4 million, or $0.01 per diluted share, in the comparable prior year period.

Liquidity and Capital Resources

For the twelve months ended December 31, 2012, BioScrip generated $49.9 million in net cash from continuing operating activities, compared to $3.1 million generated from operating activities during the twelve months of 2011, an increase of $46.7 million. This increase was primarily due to the collection of accounts receivable retained after the Pharmacy Services Asset Sale, net of accounts payable paid related to those businesses. The Company’s cash balance at the end of the fourth quarter was $62.1 million.

Outlook

Revenue in 2013 is projected to grow by 25% to 30% to a range of $830.0 million to $865.0 million and the Company is initially targeting 2013 Adjusted EBITDA of $67.0 million to $73.0 million. The range of Adjusted EBITDA reflects the on-going impact of Hurricane Sandy in the first quarter of 2013 as well as the estimated impact of competitive bidding. Additionally, revenue and Adjusted EBITDA for 2013 may be impacted by therapy mix, any lingering effects of Hurricane Sandy on the Northeast market beyond the first quarter, additional acquisitions, de novo activities, and the timing and earnings contribution from the integration of HomeChoice.

Conference Call

BioScrip will host a conference call to discuss its fourth quarter 2012 financial results on March 12, 2013 at 8:30 a.m. Eastern Time.

Interested parties may participate in the conference call by dialing 800-705-5308 (US), or 303-223-4377 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available for two weeks after the call's completion by dialing 800-633-8284 (US) or 402-977-9140 (International) and entering conference call ID number

4

21648877. An audio webcast and archive will also be available for 30 days under the “Investor Relations” section of the BioScrip website at www.bioscrip.com.

About BioScrip, Inc.

BioScrip, Inc. provides comprehensive infusion and home care solutions. By partnering with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers we are able to provide access to infusible medications and management solutions. Our goal is to optimize outcomes for chronic and other complex healthcare conditions and enhance the quality of patient life. BioScrip brings clinical competence in providing high-touch, comprehensive infusion and nursing services to patients in the most convenient ways possible. Through our customer services and treatments we aim to ensure the best possible therapy outcome.

Forward Looking Statements – Safe Harbor

This press release includes statements that may constitute "forward-looking statements," including projections of certain measures of the Company's results of operations, projections of certain charges and expenses, and other statements regarding the Company's goals, regulatory approvals and strategy.  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts.  In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "predict," "potential," "continue"  or comparable terms. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and, because such statements inherently involve risks and uncertainties, actual results may differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include but are not limited to risks associated with: the Company’s ability to grow its Infusion segment organically or through acquisitions and obtain financing in connection therewith; its ability to effectively integrate acquisitions; its ability to reduce operating costs while sustaining growth; reductions in federal, state and commercial payor reimbursement for the Company’s products and services; increased government regulation related to the health care and insurance industries; as well as the risks described in the Company's periodic filings with the Securities and Exchange Commission, including the Company’s annual report on Form 10-K for the year ended December 31, 2011. The Company does not undertake any duty to update these forward-looking statements after the date hereof, even though the Company’s situation may change in the future.  All of the forward-looking statements herein are qualified by these cautionary statements.

Reconciliation to Non-GAAP Financial Measures

In addition to reporting all financial information required in accordance with generally accepted accounting principles (GAAP), the Company is also reporting EBITDA, Adjusted EBITDA, and Adjusted EPS, which are non-GAAP financial measures.EBITDA, Adjusted EBITDA and Adjusted EPS are not measurements of financial

5

performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of our liquidity. In addition, the Company's definitions of EBITDA, Adjusted EBITDA and Adjusted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies. EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, acquisition and integration expenses, and restructuring and other expenses. As part of restructuring and other expenses, the Company may incur significant charges such as, but not limited to, the write down of certain long−lived assets, temporary redundant expenses, retraining expenses, potential cash bonus payments and potential accelerated payments or terminated costs for certain of its contractual obligations. Adjusted EPS, as defined by the Company, represents earnings per diluted share, excluding the same elements in calculating Adjusted EBITDA (restructuring and other expenses, acquisition and integration expenses, stock-based compensation expense) as well as the impact of acquisition-related intangible amortization. Management believes that these non-GAAP financial measures provide useful supplemental information regarding the performance of our business operations and facilitates comparisons to our historical operating results. For a full reconciliation of EBITDA, Adjusted EBITDA and Adjusted EPS to the most comparable GAAP financial measures, please see the attachments to this earnings release. 

Contacts:

Hai Tran

BioScrip, Inc.

952-979-3768

Lisa Wilson

In-Site Communications, Inc.

212-759-3929

(Financial Tables Follow)

6

Schedule 1

BIOSCRIP, INC

CONSOLIDATED BALANCE SHEETS

(in thousands, except for share amounts)

	December 31, 2012			December 31, 2011
ASSETS
Current assets
Cash and cash equivalents	$	62,101			—
Receivables, less allowance for doubtful accounts of $22,212 and $22,728 at December 31, 2012 and December 31, 2011, respectively		129,103			225,412
Inventory		34,034			17,997
Prepaid expenses and other current assets		10,189			10,184
Current assets from discontinued operations		—			38,876
Total current assets		235,427			292,469
Property and equipment, net		23,721			26,951
Goodwill		350,810			312,387
Intangible assets, net		17,446			19,622
Deferred financing costs		2,877			3,992
Investments in and advances to unconsolidated affiliate		10,042			—
Other non-current assets		2,053			1,552
Non-current assets from discontinued operations		—			20,129
Total assets	$	642,376			677,102
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Current portion of long-term debt	$	953			66,161
Accounts payable		34,438			79,155
Claims payable		7,411			11,766
Amounts due to plan sponsors		18,173			25,219
Accrued interest		5,803			5,825
Accrued expenses and other current liabilities		41,491			32,648
Total current liabilities		108,269			220,774
Long-term debt, net of current portion		225,426			227,298
Deferred taxes		10,291			10,295
Other non-current liabilities		4,981			3,456
Total liabilities		348,967			461,823
Stockholders' equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding		—			—
Common stock, $.0001 par value; 125,000,000 shares authorized; shares issued: 59,600,713 and 57,800,791, respectively; shares outstanding: 57,026,957 and 55,109,038, respectively		6			6
Treasury stock, shares at cost: 2,582,520 and 2,638,421, respectively		(10,311	)		(10,461	)
Additional paid-in capital		388,798			375,525
Accumulated deficit		(85,084	)		(149,791	)
Total stockholders' equity		293,409			215,279
Total liabilities and stockholders' equity	$	642,376		$	677,102

7

Schedule 2

BIOSCRIP, INC

CONSOLIDATED STATEMENTS OF OPERATIONS

 (in thousands, except per share amounts)

	Three Months Ended						Year Ended
	December 31,						December 31,
	2012			2011			2012			2011
Product revenue	$	132,785		$	100,158		$	471,506		$	365,526
Service revenue		47,953			58,107			191,131			188,980
Total revenue		180,738			158,265			662,637			554,506
Cost of product revenue		92,214			66,025			325,271			238,072
Cost of service revenue		28,131			33,642			112,406			101,019
Total cost of revenue		120,345			99,667			437,677			339,091
Gross profit		60,393			58,598			224,960			215,415
% of revenues		33.4	%		37.0	%		33.9	%		38.8	%
Selling, general and administrative expenses		49,087			42,971			184,491			167,136
Bad debt expense		3,358			3,073			14,035			11,441
Acquisition and integration expenses		2,241			—			4,046			—
Restructuring and other expenses		1,446			101			5,143			7,909
Amortization of intangibles		1,113			880			3,957			3,376
Income from operations		3,148			11,573			13,288			25,553
Interest expense, net		6,362			6,167			26,067			25,542
Net income (loss) from continuing operations,  before income taxes		(3,214	)		5,406			(12,779	)		11
Tax provision (benefit)		(1,795	)		2,841			(4,439	)		435
Net income (loss) from continuing operations, net of income taxes		(1,419	)		2,565			(8,340	)		(424	)
Net income (loss) from discontinued operations, net of income taxes		8,599			4,144			73,047			8,296
Net income (loss)	$	7,180		$	6,709		$	64,707		$	7,872
Basic weighted average shares		56,922			54,972			56,239			54,505
Diluted weighted average shares		56,922			55,608			56,239			54,505
Income (loss) per common share:
Basic loss from continuing operations	$	(0.03	)	$	0.05		$	(0.15	)	$	(0.01	)
Basic income (loss) from discontinued operations	$	0.15		$	0.07		$	1.30		$	0.15
Basic income (loss)	$	0.12		$	0.12		$	1.15		$	0.14
Diluted loss from continuing operations	$	(0.03	)	$	0.05		$	(0.15	)	$	(0.01	)
Diluted  income (loss) from discontinued operations	$	0.15		$	0.07		$	1.30		$	0.15
Diluted income (loss)	$	0.12		$	0.12		$	1.15		$	0.14

8

 Schedule 3

BIOSCRIP, INC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Years Ended December 31,
	2012			2011
Cash flows from operating activities:
Net income (loss)	$	64,707		$	7,872
Less: Income from discontinued operations, net of income taxes		73,047			8,296
Loss from continuing operations, net of income taxes		(8,340	)		(424	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation		8,513			6,591
Amortization of intangibles		3,957			3,376
Amortization of deferred financing costs		1,261			1,055
Change in deferred income tax		(4	)		1,153
Compensation under stock-based compensation plans		6,122			4,467
Loss on disposal of fixed assets		156			201
Changes in assets and liabilities, net of acquired business:
Receivables, net of bad debt expense		101,230			(31,690	)
Inventory		(15,249	)		(2,497	)
Prepaid expenses and other assets		3,726			11,211
Accounts payable		(48,200	)		(1,659	)
Claims payable		(4,354	)		8,729
Amounts due to plan sponsors		(7,046	)		5,437
Accrued interest		(22	)		59
Accrued expenses and other liabilities		8,112			(2,945	)
Net cash provided by (used in) operating activities from continuing operations	$	49,862		$	3,064
Net cash provided by (used in) operating activities from discontinued operations		(22,978	)		23,905
Net cash provided by (used in) operating activities	$	26,884		$	26,969
Cash flows from investing activities:
Purchases of property and equipment, net	$	(10,986	)	$	(7,853	)
Cash consideration paid for asset acquisitions		(43,046	)		(463	)
Cash consideration paid to DS Pharmacy		(2,935	)		—
Cash consideration paid for unconsolidated affiliate, net of cash acquired		(10,652	)		—
Net cash provided by (used in) investing activities from continuing operations		(67,619	)		(8,316	)
Net cash provided by (used in) investing activities from discontinued operations		161,499			(1,591	)
Net cash used in investing activities	$	93,880		$	(9,907	)
Cash flows from financing activities:
Borrowings on line of credit		1,244,050			1,773,644
Repayments on line of credit		(1,307,872	)		(1,791,058	)
Repayments of capital leases		(3,278	)		(2,635	)
Deferred and other financing costs		—			(22	)
Net proceeds from exercise of employee stock compensation plans		8,611			3,198
Surrender of stock to satisfy minimum tax withholding		(174	)		(189	)
Net cash provided by (used in) financing activities from continuing operations		(58,663	)		(17,062	)
Net cash provided by (used in) financing activities from discontinued operations		—			—
Net cash (used in) provided by financing activities	$	(58,663	)	$	(17,062	)
Net change in cash and cash equivalents		62,101			—
Cash and cash equivalents - beginning of period		—			—
Cash and cash equivalents - end of period	$	62,101			—
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	$	25,589		$	27,528
Cash paid during the period for income taxes	$	2,757		$	1,042
DISCLOSURE OF NON-CASH TRANSACTIONS:
Capital lease obligations incurred to acquire property and equipment	$	20		$	6,631

9

Schedule 4

BIOSCRIP, INC

Reconciliation between GAAP and Non-GAAP Measures

(in thousands)

	Three Months Ended						Years Ended
	December 31,						December 31,
	2012			2011			2012			2011
Results of Operations:
Revenue:
Infusion Services - product revenue	$	132,785		$	100,158		$	471,506		$	365,526
Infusion Services - service revenue		2,838			2,301			10,080			8,756
Total Infusion Services revenue		135,623			102,459			481,586			374,282
Home Health Services - service revenue		18,320			17,206			69,190			69,635
PBM Services - service revenue		26,795			38,600			111,861			110,589
Total revenue	$	180,738		$	158,265		$	662,637		$	554,506
Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	11,024		$	9,947		$	36,764		$	35,128
Home Health Services		1,844			1,498			5,401			5,954
PBM Services		6,292			9,274			25,659			30,122
Total Segment Adjusted EBITDA		19,160			20,719			67,824			71,204
Corporate overhead		(7,090	)		(5,853	)		(26,755	)		(23,308	)
Consolidated Adjusted EBITDA		12,070			14,866			41,069			47,896
Interest expense, net		(6,362	)		(6,167	)		(26,067	)		(25,542	)
Income tax (expense) benefit		1,795			(2,841	)		4,439			(435	)
Depreciation		(2,398	)		(1,828	)		(8,513	)		(6,591	)
Amortization of intangibles		(1,113	)		(880	)		(3,957	)		(3,376	)
Stock-based compensation expense		(1,724	)		(484	)		(6,122	)		(4,467	)
Acquisition and integration expenses		(2,241	)		-			(4,046	)		—
Restructuring and other expenses		(1,446	)		(101	)		(5,143	)		(7,909	)
Net (loss) income:	$	(1,419	)	$	2,565		$	(8,340	)	$	(424	)
Supplemental Operating Data
Capital Expenditures:
Infusion Services							$	6,685		$	4,826
Home Health Services								171			170
PBM Services								0			0
Corporate unallocated								4,130			2,857
Total							$	10,986		$	7,853
Depreciation Expense:
Infusion Services							$	4,347		$	5,242
Home Health Services								111			48
PBM Services								0			0
Corporate unallocated								4,055			1,301
Total							$	8,513		$	6,591
Total Assets
Infusion Services							$	438,623		$	353,999
Home Health Services								62,403			64,672
PBM Services								36,354			40,418
Corporate unallocated								95,813			24,348
Assets from discontinued operations								0			59,005
Assets associated with discontinued operations, not sold								9,183			134,660
Total							$	642,376		$	677,102
Goodwill
Infusion Services							$	304,282		$	265,859
Home Health Services								33,784			33,784
PBM Services								12,744			12,744
Total							$	350,810		$	312,387

10

Schedule 5

BIOSCRIP, INC

Reconciliation between GAAP and Non-GAAP Earnings Per Share

(in thousands)

	Three Months Ended					Years Ended
	December 31,					December 31,
	2012 1,2			2011 3,4		2012 5,6			2011 7,8
Net income from continuing operations	$	(1,419	)	$	2,565	$	(8,340	)	$	(424	)
Non-GAAP adjustments:
Restructuring and other expenses		871			61		3,099			4,798
Acquisition and integration expenses		1,350			-		2,438			-
Amortization of intangibles		671			534		2,384			2,048
Compensation under stock-based compensation plans		1,039			294		3,689			2,710
Non-GAAP Net income from continuing operations	$	2,512		$	3,454	$	3,270		$	9,132
Earnings per share from continuing operations, basic and diluted	$	(0.03	)	$	0.05	$	(0.15	)	$	(0.01	)
Non-GAAP adjustments:
Restructuring and other related costs		0.02			-		0.06			0.09
Acquisition and integration expenses		0.02			-		0.04			-
Amortization of intangibles		0.01			0.01		0.04			0.04
Compensation under stock-based compensation plans		0.02			0.01		0.07			0.05
Non-GAAP earnings per share from continuing operations, basic and diluted	$	0.04		$	0.07	$	0.06		$	0.17
Weighted average shares outstanding, basic		56,922			54,972		56,239			54,505
Weighted average shares outstanding, diluted		57,948			55,608		57,001			55,150

11

Schedule 5

BIOSCRIP, INC

Reconciliation between GAAP and Non-GAAP Earnings Per Share

(in thousands)

(1)	For the three months ended December 31, 2012, non-GAAP net income from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $575, $891, $442, and $685 respectively.
(2)	For the three months ended December 31, 2012, non-GAAP Adjusted EPS per basic and diluted share from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense per basic and diluted share netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $(0.01), $(0.02), $(0.01), and $(0.01) per share, respectively.
(3)	For the three months ended December 31, 2011, non-GAAP net income from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense netted against restructuring and other expenses, amortization of intangibles, and stock-based compensation expense was $40, $346, and $190, respectively.
(4)	For the three months ended December 31, 2011, non-GAAP Adjusted EPS per basic and diluted share from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense per basic and diluted share netted against restructuring and other expenses, amortization of intangibles, and stock-based compensation expense were $(0.00), $(0.01), and $(0.00) per share, respectively.
(5)	For the year ended December 31, 2012, non-GAAP net income from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $2,044, $1,608, 1,573, and $2,433, respectively.
(6)	For the year ended December 31, 2012, non-GAAP Adjusted EPS per basic and diluted share from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense per basic and diluted share netted against restructuring and other expenses, acquisition and integration expenses, amortization of intangibles, and stock-based compensation expense was $(0.04), $(0.03), $(0.03), and $(0.04) per share, respectively.
(7)	For the year ended December 31, 2011, non-GAAP net income from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense netted against restructuring and other expenses, amortization of intangibles, and stock-based compensation expense was $3,111, $1,328, and $1,757, respectively.
(8)	For the year ended December 31, 2011, non-GAAP Adjusted EPS per basic and diluted share from continuing operations adjustments are net of tax, calculated using an annual effective tax rate method.  The tax expense per basic and diluted share netted against restructuring and other expenses, amortization of intangibles, and stock-based compensation expense were $(0.06), $(0.02), and $(0.03) per share, respectively.

12